The ruling, made today, means that Bayer has won its legal dispute over the parallel imports of a cardiovascular medicine with the European Commission, and that a fine imposed earlier has been annulled.
"This ruling is very encouraging for an industry that has especially suffered from the problems arising from parallel trade," said Dr Trevor Jones, Director General of the ABPI.
"I this will establish a positive way forward for innovative medicines both now and in the future, so that we can achieve a more rational trade environment in Europe."
Parallel trade arises because prices of medicines are largely controlled by individual member states of the EU, often leading to wide variations that are not the choice of the manufacturer.
Latest figures show that parallel trade costs the industry some £1.4 billion a year, and that more than one in eight prescriptions in the UK are filled with a parallel-imported product.
For further information, please contact: ABPI Press Office 020 7747 1410